Zolbetuximab
(Redirected from IMAB362)
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric |
Target | CLDN18.2 |
Clinical data | |
Other names | IMAB362; Claudiximab |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
![]() ![]() |
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1]
The drug is in phase III clinical trials as of November 2021[update].[2]
Preliminary results from the phase II 'FAST' trial in June 2016 suggest it is helpful for advanced gastric cancer.[3]
References
- ^ "Our mission - Ganymed Pharmaceuticals GmbH - Ganymed Pharmaceuticals GmbH". www.ganymed-pharmaceuticals.de.
- ^ "A Study of Zolbetuximab (IMAB362)". clinicaltrials.gov. 19 November 2021.
- ^ "Antibody Shines in Advanced Gastric Cancer". medpagetoday.com. 5 June 2016.
Categories:
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Articles containing potentially dated statements from November 2021
- All articles containing potentially dated statements
- Monoclonal antibodies
- Experimental drugs
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs